ArticleTranslational cancer research2025
Vitamin D-regulated miRNA expression in tumoral and normal adjacent tissue of localized gastric cancer patients: the impact on survival and time to relapse.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vitamin D and Gastric Cancer: A Systematic Review and Meta-Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Vitamin D in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is driven by genetic, epigenetic, and environmental factors, with dysregulated microRNAs (miRNAs) influencing key biological processes and vitamin D signaling through vitamin D receptor modulation, impacting tumor prognosis. The aim of this study is to correlate the expression of vitamin D-related miRNAs in tumor tissue and normal adjacent tissue (NAT) in GC with patient survival. Methods: The study involved 77 patients with localized GC, with time to relapse (TTR) and overall survival (OS) as primary and secondary endpoints, respectively. The study investigated miRNA expression levels in NAT and tumor and their association with patient characteristics. Results: The analysis revealed that miR-106b, miR-181b-5p, miR-181a-5p and miR-181d-5p were upregulated in tumor tissue, whereas miR-143 and miR-145 were downregulated. Patients with vitamin D deficiency (levels <30 ng/mL) showed downregulation of miR-145 in the NAT (P=0.02). The study found that downregulation of miR-181b-5p, miR-106b, and miR-181c-5p in NAT correlated with higher relapse risk (P=0.02, P=0.003, P=0.03). Furthermore, lower OS rates were significantly linked to the downregulation of miR-106b and miR-99b-3p in NAT (P<0.001, P=0.004). These findings indicate that specific miRNA downregulation in NAT is associated with poorer prognosis and increased relapse likelihood in GC patients. Additionally, miRNA expression patterns in NAT may indicate a predisposition to tumor recurrence. Conclusions: The study concludes that miRNA dysregulation in non-neoplastic gastric mucosa suggests these tissues may be cancer-prone environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.